ATH 25.0% 0.5¢ alterity therapeutics limited

Dr. Sinclair has 77 different publications in PubMed telling...

  1. 2,713 Posts.
    lightbulb Created with Sketch. 941
    Calorierestrictionmimetics...sirtuins,etc.Startingtodiveintoawholenewoceanofunfamiliarterms,processes,andheapsofdata.Howtogetthehealthbenefitsoffasting(avoidingthedownsides),chemically?

    Strangely,haverecentlynotedthementionoffastingmakingsubtlealterations(hmmm...perhapsduetothesirtuins)thatholdsomenegativeprocessesatbay,indisparatepublications.UnitingwithDavidSinclairseemstohavethepotentialtoopen"interestingdoors."Lookingforwardtothejourney.

    Abigthankyoupivalde,forinitiatingtheintegration.

    Other:WeseemtobemissingaSkint,M1...,Pierre,etc.andotherkeycontributors.I'mhopingyoufolkshaven'tsuccumbedtotallglassesdrippingcondensationwithlittleumbrellasbobbingupanddown.AlsohopingsomeluminariesfromSinclair'sother"alliedentities"willjointheconversation.

    'noughsaid...
    Dr. Sinclair has 77 different publications in PubMed telling something about sirtuins. This paper below is a review but it is not a free paper. He has now bought Prana, changed it to Alterity Therapeutics. He must believe that PBT434 ( or also PBT2 ) will make a difference in sirtuin modulation and aging.
    Here you can find the sirtuin publications by Dr. Sinclair : https://www.ncbi.nlm.nih.gov/pubmed/?term=Sinclair+DA%2C+sirtuin

    Pharmacol Ther. 2018 Aug;188:140-154. doi: 10.1016/j.pharmthera.2018.03.004. Epub 2018 Mar 22.

    Sirtuin activators and inhibitors: Promises, achievements, and challenges.

    Abstract

    The NAD+-dependent protein lysine deacylases of the Sirtuin family regulate various physiological functions, from energy metabolism to stress responses. The human Sirtuin isoforms, SIRT1-7, are considered attractive therapeutic targets for aging-related diseases, such as type 2 diabetes, inflammatory diseases and neurodegenerative disorders. We review the status of Sirtuin-targeted drug discovery and development. Potent and selective pharmacological Sirt1 activators and inhibitors are available, and initial clinical trials have been carried out. Several promising inhibitors and activators have also been described for other isoforms. Progress in understanding the mechanisms of Sirtuin modulation by such compounds provides a rational basis for further drug development.


 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
46 57663299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 56205001 43
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 29/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.